After three years with the Australian Stem Cell Centre (ASCC), Dr Dianna DeVore has resigned as vice-president of clinical cardiac development, and will be returning to California to pursue stem cell collaborative opportunities, effective December 31. [ + ]

A US$6 million fund was launched today for joint Israeli-Victorian projects in areas such as biotechnology, healthcare, nanotechnology, environmental technologies and advanced manufacturing. [ + ]

Following the resignation of CogState chief executive officer Peter Bick, Brad O'Connor has been promoted internally from chief financial officer to the CEO role. [ + ]

Shareholders in Regenera (ASX:RGA) have been asked to attend a meeting in Perth between Christmas and New Year, as the company seeks to revise terms of its planned merger with US firm Advanced Ocular Systems (AOS). [ + ]

On Friday, Biota Holdings (ASX:BTA) introduced Peter Cook as its new CEO and managing director, replacing Peter Molloy. On his first day at the company, Cook spoke with Ruth Beran about his background, the future for the company and the similarities between orbital engines and biotechnology. [ + ]

Researchers at Sydney's Garvan Medical Research Institute may have provided an explanation for the dramatic breakdown of champion Australian marathon runner Lisa Martin-Ondieki at the Barcelona Olympics in 1992. [ + ]

UK firm Domantis, 36 per cent owned by Peptech (ASX:PTD), has signed an agreement with global pharma Bristol-Myers Squibb (NYSE:BMY) to develop domain-antibody (dAb) therapeutics for multiple immunology and cancer targets. [ + ]

Brisbane biopharma Alchemia (ASX:ACL) will commence a collaborative research project next year with the University of Queensland through its preclinical service provider, TetraQ to develop a new generation of opioid-based painkillers to treat severe pain. [ + ]

Two deadlines have come and gone, and a third expires today for Melbourne gene-testing company Genetic Technologies (ASX:GTG; NASDAQ:GENE) and US firm Applera, who were due to announce a resolution of their licensing dispute in California today. [ + ]

Prima Biomed (ASX:PRR) has received the first payment of US$500,000 from Toronto-based immunology company Trillium Therapeutics following the settlement of the sale of Prima's subsidiary Arthron. [ + ]

Melbourne biopharma Anadis (ASX:ANX) has announced that antibody extracts from the colostrum of immunised dairy cows completely protects cells from the lining of the human lung against deadly anthrax toxin in vitro. [ + ]

The newly-funded Cooperative Research Centre for National Plant Biosecurity has announced the appointment of Dr Simon McKirdy as its chief executive officer.

Medical Therapies has completed its IPO capital raising over-subscribed and is likely to list on the ASX on December 9. This is the fourth listing date for the company which issued a replacement prospectus following an unsuccessful attempt to list on the ASX in August. [ + ]

Peter Cook is Biota Holdings' (ASX:BTA) new CEO and managing director, starting next Friday. [ + ]

Auckland biopharma Neuren Pharmaceuticals (ASX: NEU) has raised AUD$6.36 million to fund the acceleration of the clinical trial program for Glypromate and NNZ-2566. [ + ]